SQZ Biotechnologies Publishes Preclinical Research Demonstrating SQZ® AAC Platform's Potential as an Effective Red Blood Cell-Derived Immunotherapy

(marketscreener.com) Activating Antigen Carriers Shown Preclinically to Activate CD8 T Cells, Increase Their Tumor Infiltration and Drive Tumor KillingDemonstrated Improved Efficacy of AAC Therapy Through Combination with Chemotherapy Agenthttps://www.marketscreener.com/quote/stock/SQZ-BIOTECHNOLOGIES-COMPA-114383843/news/SQZ-Biotechnologies-Publishes-Preclinical-Research-Demonstrating-SQZ-AAC-Platform-s-Potential-as-an-41913415/?utm_medium=RSS&utm_content=20221003